Ubs Oconnor LLC Chemo Centryx, Inc. Transaction History

Ubs Oconnor LLC

  • $1.72 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
N/A
-2,730,923 Closed
0 $0
Q3 2022

May 15, 2023
BUY
$22.17 - $51.8 $60.5 Million - $141 Million
2,730,923 New
2,730,923 $141 Billion

Others Institutions Holding CCXI

# of Institutions
6
Shares Held
66.3K
Call Options Held
0
Put Options Held
0
View Full List

About ChemoCentryx, Inc.

CCXI Quotes by TradingView
  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email